Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.030 -0.010 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Allogene Therapeutics ↗
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: 
Via Benzinga
News headline image
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Apple, Amazon, HP And Other Big Losers From Friday ↗
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
News headline image
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Allogene Therapeutics ↗
  Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗
  
Via Benzinga
News headline image
Allogene Therapeutics: Q2 Earnings Insights ↗
  Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022 ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
  
Via Benzinga
News headline image
89 Biggest Movers From Friday ↗
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Allogene Therapeutics ↗
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma ↗
Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
News headline image
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity ↗
Allogene Therapeutics Inc (NASDAQ: ALLO) announced the  
Via Benzinga
News headline image
Recap: Allogene Therapeutics Q4 Earnings ↗
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Allogene Therapeutics Earnings Preview ↗
Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
News headline image
FDA Lifts Clinical Hold On Allogene's CAR-T Trials ↗
The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.